Skip to content
ADMETatlas
peptide evidence atlas
Home
About
Home

Browse

PeptidesProductsEvidenceContext signalsDescriptors

Developability

ProfileComparator

Resources

ManualExplanationsStatisticsDownloadLicenseAbout
  1. Home
  2. Peptides
  3. ATLPC0015133
Peptide·plain sequence-like

ATLPC0015133

ATLPC0015133

HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGGGGGGSGGGGSGGGGSAESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTL…

Routes
Compare in workbenchDownload releaseAPI JSON
  • Length
    275 aa
  • Monoisotopic mass
    29822.6 Da
  • Net charge @ pH 7.4
    -6.40
  • Isoelectric point
    5.38
  • GRAVY
    -0.535
On this page
  • 01 Sequence & molecular identity
  • 02 Physicochemical profile
  • 03 Exposure / Absorption
  • 04 Distribution / Barrier
  • 05 Excretion / Persistence
  • 06 Evidence landscape
  • 07 Product context
  • 08 Identity & reference map
  • 09 Data access & reproducibility
Coveragecounts only · not riskATLPC0015133
  • Measurements
    15
  • Endpoints
    7
  • Domains
    3/5
  • Products
    —
  • No matrix stability evidence
  • 3 clearance measurements
  • No immunogenicity context
  • 4 liability motifs
Jump to domain

Open the matching evidence section below

All evidence index · 15
Exposure / Absorption
7 measurements
Distribution / Barrier
5 measurements
Metabolic & Proteolytic Stability
No evidence
Excretion / Persistence
3 measurements
Toxicity / Safety
No evidence
01

Sequence & molecular identity

1 forms

Reviewed sequence, peptidoform forms, chemical representation, 3D references, and covalent topology used to interpret this peptide identity.

Sequence & peptidoform

·
Identity summaryCanonical sequence only
Identity status
Canonical sequence only
Residues
275
Peptidoform features
0
Documented molecular forms
1
Representations
2
Documented molecular forms1 form linked to this peptide identity
FormTopologyModificationsConnectionsRepresentationsMeasurements
ATLPF0016617———Notation only—
Residue view
Residue display
275 residues
H1G2E3G4T5F6T7S8D9V10S11S12Y13L14E15E16Q17A18A19K20E21F22I23A24W25L26V27K28G29G30G31G32G33G34G35S36G37G38G39G40S41G42G43G44G45S46A47E48S49K50Y51G52P53P54C55P56P57C58P59A60P61E62A63A64G65G66P67S68V69F70L71F72P73P74K75P76K77D78T79L80M81I82S83R84T85P86E87V88T89C90V91V92V93D94V95S96Q97E98D99P100E101V102Q103F104N105W106Y107V108D109G110V111E112V113H114N115A116K117T118K119P120R121E122E123Q124F125N126S127T128Y129R130V131V132S133V134L135T136V137L138H139Q140D141W142L143N144G145K146E147Y148K149C150K151V152S153N154K155G156L157P158S159S160I161E162K163T164I165S166K167A168K169G170Q171P172R173E174P175Q176V177Y178T179L180P181P182S183Q184E185E186M187T188K189N190Q191V192S193L194T195C196L197V198K199G200F201Y202P203S204D205I206A207V208E209W210E211S212N213G214Q215P216E217N218N219Y220K221T222T223P224P225V226L227D228S229D230G231S232F233F234L235Y236S237R238L239T240V241D242K243S244R245W246Q247E248G249N250V251F252S253C254S255V256M257H258E259A260L261H262N263H264Y265T266Q267K268S269L270S271L272S273L274G275
Side-chain classNonpolarPolarBasic (+)Acidic (−)Modified

Soft tints mark standard side-chain classes for scanning. Primary emphasis is reserved for reported modifications, termini, secondary-structure tracks, and topology links.

Peptidoform features

Features are shown only when a reported notation or topology record supports them.

No terminal modification, residue-level marker, disulfide, staple, coordination, or other topology signal is currently available.

Structure & chemistry

·
Chemical representationsequence / HELM only
Representation class

How the current release can interpret this identity chemically.

plain sequence-like
Parent-residue sequence

Residue string used for positional interpretation when available.

HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGGGGGGSGGGGSGGGGSAESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG
HELM

Polymer notation for modified peptide representation when available.

Not available
SMILES

Chemical graph string used for atom-level 2D depiction when available.

Not available
No atom-level graph

A reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.

3D structure references10 references
Structure reference·
3D coordinates·Sequence matchexperimental
Sequence match·reference selected·identity 100.0%·confidence experimental
LinkMethodConfidenceMatch
OpenSequence matchexperimental100.0% identity
OpenSequence matchexperimental99.1% identity
OpenSequence matchexperimental99.1% identity
OpenSequence matchexperimental99.1% identity
OpenSequence matchexperimental99.1% identity
OpenSequence matchexperimental99.1% identity
OpenSequence matchexperimental98.6% identity
OpenSequence matchexperimental98.6% identity
OpenSequence matchexperimental98.6% identity
OpenSequence matchexperimental98.2% identity
Covalent topology & modificationsnone
Exact topology not established

No reviewed form-level topology or residue-level connection annotation is attached to this peptide in the current release. This is not evidence that every molecular form is linear or unmodified.

02

Physicochemical profile

4 descriptors

Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity. Computed values are interpretation aids, not experimental ADMET measurements.

·
Core descriptors275 aa · pI 5.4 · GRAVY -0.54
Length
275 aa
Monoisotopic mass
29822.57 Da
Average mass
29841.30 Da
Net charge at pH 7.4
-6.40
Estimated pI
5.38
GRAVY
-0.535
KD-positive residues
28.4%
Aromatic residues
9.1%
Developability interpretation
Ionization context
pH 7.4 separated from pI
Hydrophobicity balance
Leans hydrophilic
Amphipathic moment (μH)
0.07
Computation boundary
Standard-sequence only
Charge & residue composition
pH charge context

Modeled net charge across common formulation and assay pH checkpoints.

pH 2
31.68
pH 5
2.05
pH 6
-2.11
pH 7.4
-6.84
pH 9
-13.29
pH 12
-43.19
Residue-class composition

Grouped composition is often more interpretable than a long amino-acid list.

Acidic (D,E)
32 · 11.6%
Basic (K,R,H)
31 · 11.3%
Polar uncharged (N,Q,S,T)
68 · 24.7%
Hydrophobic aliphatic (A,V,I,L,M)
62 · 22.5%
Aromatic (F,W,Y)
25 · 9.1%
Conformational / sulfur (G,P,C)
57 · 20.7%
Top residues
G2910.5%S2910.5%V259.1%E228.0%P228.0%K196.9%L186.5%T165.8%
Hydropathy & amphipathic windows
Hydropathy windows

Seven-residue sliding windows expose local patches hidden by whole-sequence GRAVY.

Most hydrophobic window
131-137
VVSVLTV
GRAVY 2.729
Most hydrophilic window
117-123
KTKPREE
GRAVY -3.086
269 local hydropathy windows scanned. A local patch is context for solubility, adsorption, and membrane interaction review, not a standalone endpoint.
Amphipathic-window scan

Top alpha-helix hydrophobic-moment windows across 12, 15, 18, and 21 residues.

12 aa window
17-28
QAAKEFIAWLVK
μH 1.74 · charge 1.0
12 aa window
157-168
LPSSIEKTISKA
μH 1.59 · charge 1.0
12 aa window
155-166
KGLPSSIEKTIS
μH 1.55 · charge 1.0
12 aa window
156-167
GLPSSIEKTISK
μH 1.48 · charge 1.0
12 aa window
19-30
AKEFIAWLVKGG
μH 1.47 · charge 1.0
Sequence-liability cues
Sequence-liability notes

Motifs are review prompts for formulation or CMC interpretation; they are not degradation predictions.

Asn deamidation motif
NG, NS · pos 126, 144, 213
Asn followed by small/polar residues is a known sequence context to review for deamidation susceptibility.
Asp isomerization motif
DG, DP, DS, DT · pos 78, 99, 109, 228, 230
Asp-containing motifs can merit review for isomerization or related degradation pathways.
Oxidation-sensitive residues
M, W, C · pos 25, 55, 58, 81, 90, 106 +8
Met, Trp, and Cys residues can merit formulation review for oxidation or covalent-state sensitivity.
Cys covalent complexity
C · pos 55, 58, 90, 150, 196, 254
Multiple cysteines can indicate disulfide or free-thiol interpretation requirements.
Alpha-helix amphipathic projection
Helical wheel · Edmundson projection
μH = 0.07100°/residue · 275 aa
μH1: H (His) · Basic + · K-D -3.2H12: G (Gly) · Special · K-D -0.4G3: E (Glu) · Acidic − · K-D -3.5E4: G (Gly) · Special · K-D -0.4G5: T (Thr) · Polar · K-D -0.7T56: F (Phe) · Aromatic · K-D 2.8F7: T (Thr) · Polar · K-D -0.7T8: S (Ser) · Polar · K-D -0.8S9: D (Asp) · Acidic − · K-D -3.5D10: V (Val) · Hydrophobic · K-D 4.2V1011: S (Ser) · Polar · K-D -0.8S12: S (Ser) · Polar · K-D -0.8S13: Y (Tyr) · Aromatic · K-D -1.3Y14: L (Leu) · Hydrophobic · K-D 3.8L15: E (Glu) · Acidic − · K-D -3.5E1516: E (Glu) · Acidic − · K-D -3.5E17: Q (Gln) · Polar · K-D -3.5Q18: A (Ala) · Hydrophobic · K-D 1.8A19: A (Ala) · Hydrophobic · K-D 1.8A20: K (Lys) · Basic + · K-D -3.9K2021: E (Glu) · Acidic − · K-D -3.5E22: F (Phe) · Aromatic · K-D 2.8F23: I (Ile) · Hydrophobic · K-D 4.5I24: A (Ala) · Hydrophobic · K-D 1.8A25: W (Trp) · Aromatic · K-D -0.9W2526: L (Leu) · Hydrophobic · K-D 3.8L27: V (Val) · Hydrophobic · K-D 4.2V28: K (Lys) · Basic + · K-D -3.9K29: G (Gly) · Special · K-D -0.4G30: G (Gly) · Special · K-D -0.4G3031: G (Gly) · Special · K-D -0.4G32: G (Gly) · Special · K-D -0.4G33: G (Gly) · Special · K-D -0.4G34: G (Gly) · Special · K-D -0.4G35: G (Gly) · Special · K-D -0.4G3536: S (Ser) · Polar · K-D -0.8S37: G (Gly) · Special · K-D -0.4G38: G (Gly) · Special · K-D -0.4G39: G (Gly) · Special · K-D -0.4G40: G (Gly) · Special · K-D -0.4G4041: S (Ser) · Polar · K-D -0.8S42: G (Gly) · Special · K-D -0.4G43: G (Gly) · Special · K-D -0.4G44: G (Gly) · Special · K-D -0.4G45: G (Gly) · Special · K-D -0.4G4546: S (Ser) · Polar · K-D -0.8S47: A (Ala) · Hydrophobic · K-D 1.8A48: E (Glu) · Acidic − · K-D -3.5E49: S (Ser) · Polar · K-D -0.8S50: K (Lys) · Basic + · K-D -3.9K5051: Y (Tyr) · Aromatic · K-D -1.3Y52: G (Gly) · Special · K-D -0.4G53: P (Pro) · Special · K-D -1.6P54: P (Pro) · Special · K-D -1.6P55: C (Cys) · Special · K-D 2.5C5556: P (Pro) · Special · K-D -1.6P57: P (Pro) · Special · K-D -1.6P58: C (Cys) · Special · K-D 2.5C59: P (Pro) · Special · K-D -1.6P60: A (Ala) · Hydrophobic · K-D 1.8A6061: P (Pro) · Special · K-D -1.6P62: E (Glu) · Acidic − · K-D -3.5E63: A (Ala) · Hydrophobic · K-D 1.8A64: A (Ala) · Hydrophobic · K-D 1.8A65: G (Gly) · Special · K-D -0.4G6566: G (Gly) · Special · K-D -0.4G67: P (Pro) · Special · K-D -1.6P68: S (Ser) · Polar · K-D -0.8S69: V (Val) · Hydrophobic · K-D 4.2V70: F (Phe) · Aromatic · K-D 2.8F7071: L (Leu) · Hydrophobic · K-D 3.8L72: F (Phe) · Aromatic · K-D 2.8F73: P (Pro) · Special · K-D -1.6P74: P (Pro) · Special · K-D -1.6P75: K (Lys) · Basic + · K-D -3.9K7576: P (Pro) · Special · K-D -1.6P77: K (Lys) · Basic + · K-D -3.9K78: D (Asp) · Acidic − · K-D -3.5D79: T (Thr) · Polar · K-D -0.7T80: L (Leu) · Hydrophobic · K-D 3.8L8081: M (Met) · Hydrophobic · K-D 1.9M82: I (Ile) · Hydrophobic · K-D 4.5I83: S (Ser) · Polar · K-D -0.8S84: R (Arg) · Basic + · K-D -4.5R85: T (Thr) · Polar · K-D -0.7T8586: P (Pro) · Special · K-D -1.6P87: E (Glu) · Acidic − · K-D -3.5E88: V (Val) · Hydrophobic · K-D 4.2V89: T (Thr) · Polar · K-D -0.7T90: C (Cys) · Special · K-D 2.5C9091: V (Val) · Hydrophobic · K-D 4.2V92: V (Val) · Hydrophobic · K-D 4.2V93: V (Val) · Hydrophobic · K-D 4.2V94: D (Asp) · Acidic − · K-D -3.5D95: V (Val) · Hydrophobic · K-D 4.2V9596: S (Ser) · Polar · K-D -0.8S97: Q (Gln) · Polar · K-D -3.5Q98: E (Glu) · Acidic − · K-D -3.5E99: D (Asp) · Acidic − · K-D -3.5D100: P (Pro) · Special · K-D -1.6P100101: E (Glu) · Acidic − · K-D -3.5E102: V (Val) · Hydrophobic · K-D 4.2V103: Q (Gln) · Polar · K-D -3.5Q104: F (Phe) · Aromatic · K-D 2.8F105: N (Asn) · Polar · K-D -3.5N105106: W (Trp) · Aromatic · K-D -0.9W107: Y (Tyr) · Aromatic · K-D -1.3Y108: V (Val) · Hydrophobic · K-D 4.2V109: D (Asp) · Acidic − · K-D -3.5D110: G (Gly) · Special · K-D -0.4G110111: V (Val) · Hydrophobic · K-D 4.2V112: E (Glu) · Acidic − · K-D -3.5E113: V (Val) · Hydrophobic · K-D 4.2V114: H (His) · Basic + · K-D -3.2H115: N (Asn) · Polar · K-D -3.5N115116: A (Ala) · Hydrophobic · K-D 1.8A117: K (Lys) · Basic + · K-D -3.9K118: T (Thr) · Polar · K-D -0.7T119: K (Lys) · Basic + · K-D -3.9K120: P (Pro) · Special · K-D -1.6P120121: R (Arg) · Basic + · K-D -4.5R122: E (Glu) · Acidic − · K-D -3.5E123: E (Glu) · Acidic − · K-D -3.5E124: Q (Gln) · Polar · K-D -3.5Q125: F (Phe) · Aromatic · K-D 2.8F125126: N (Asn) · Polar · K-D -3.5N127: S (Ser) · Polar · K-D -0.8S128: T (Thr) · Polar · K-D -0.7T129: Y (Tyr) · Aromatic · K-D -1.3Y130: R (Arg) · Basic + · K-D -4.5R130131: V (Val) · Hydrophobic · K-D 4.2V132: V (Val) · Hydrophobic · K-D 4.2V133: S (Ser) · Polar · K-D -0.8S134: V (Val) · Hydrophobic · K-D 4.2V135: L (Leu) · Hydrophobic · K-D 3.8L135136: T (Thr) · Polar · K-D -0.7T137: V (Val) · Hydrophobic · K-D 4.2V138: L (Leu) · Hydrophobic · K-D 3.8L139: H (His) · Basic + · K-D -3.2H140: Q (Gln) · Polar · K-D -3.5Q140141: D (Asp) · Acidic − · K-D -3.5D142: W (Trp) · Aromatic · K-D -0.9W143: L (Leu) · Hydrophobic · K-D 3.8L144: N (Asn) · Polar · K-D -3.5N145: G (Gly) · Special · K-D -0.4G145146: K (Lys) · Basic + · K-D -3.9K147: E (Glu) · Acidic − · K-D -3.5E148: Y (Tyr) · Aromatic · K-D -1.3Y149: K (Lys) · Basic + · K-D -3.9K150: C (Cys) · Special · K-D 2.5C150151: K (Lys) · Basic + · K-D -3.9K152: V (Val) · Hydrophobic · K-D 4.2V153: S (Ser) · Polar · K-D -0.8S154: N (Asn) · Polar · K-D -3.5N155: K (Lys) · Basic + · K-D -3.9K155156: G (Gly) · Special · K-D -0.4G157: L (Leu) · Hydrophobic · K-D 3.8L158: P (Pro) · Special · K-D -1.6P159: S (Ser) · Polar · K-D -0.8S160: S (Ser) · Polar · K-D -0.8S160161: I (Ile) · Hydrophobic · K-D 4.5I162: E (Glu) · Acidic − · K-D -3.5E163: K (Lys) · Basic + · K-D -3.9K164: T (Thr) · Polar · K-D -0.7T165: I (Ile) · Hydrophobic · K-D 4.5I165166: S (Ser) · Polar · K-D -0.8S167: K (Lys) · Basic + · K-D -3.9K168: A (Ala) · Hydrophobic · K-D 1.8A169: K (Lys) · Basic + · K-D -3.9K170: G (Gly) · Special · K-D -0.4G170171: Q (Gln) · Polar · K-D -3.5Q172: P (Pro) · Special · K-D -1.6P173: R (Arg) · Basic + · K-D -4.5R174: E (Glu) · Acidic − · K-D -3.5E175: P (Pro) · Special · K-D -1.6P175176: Q (Gln) · Polar · K-D -3.5Q177: V (Val) · Hydrophobic · K-D 4.2V178: Y (Tyr) · Aromatic · K-D -1.3Y179: T (Thr) · Polar · K-D -0.7T180: L (Leu) · Hydrophobic · K-D 3.8L180181: P (Pro) · Special · K-D -1.6P182: P (Pro) · Special · K-D -1.6P183: S (Ser) · Polar · K-D -0.8S184: Q (Gln) · Polar · K-D -3.5Q185: E (Glu) · Acidic − · K-D -3.5E185186: E (Glu) · Acidic − · K-D -3.5E187: M (Met) · Hydrophobic · K-D 1.9M188: T (Thr) · Polar · K-D -0.7T189: K (Lys) · Basic + · K-D -3.9K190: N (Asn) · Polar · K-D -3.5N190191: Q (Gln) · Polar · K-D -3.5Q192: V (Val) · Hydrophobic · K-D 4.2V193: S (Ser) · Polar · K-D -0.8S194: L (Leu) · Hydrophobic · K-D 3.8L195: T (Thr) · Polar · K-D -0.7T195196: C (Cys) · Special · K-D 2.5C197: L (Leu) · Hydrophobic · K-D 3.8L198: V (Val) · Hydrophobic · K-D 4.2V199: K (Lys) · Basic + · K-D -3.9K200: G (Gly) · Special · K-D -0.4G200201: F (Phe) · Aromatic · K-D 2.8F202: Y (Tyr) · Aromatic · K-D -1.3Y203: P (Pro) · Special · K-D -1.6P204: S (Ser) · Polar · K-D -0.8S205: D (Asp) · Acidic − · K-D -3.5D205206: I (Ile) · Hydrophobic · K-D 4.5I207: A (Ala) · Hydrophobic · K-D 1.8A208: V (Val) · Hydrophobic · K-D 4.2V209: E (Glu) · Acidic − · K-D -3.5E210: W (Trp) · Aromatic · K-D -0.9W210211: E (Glu) · Acidic − · K-D -3.5E212: S (Ser) · Polar · K-D -0.8S213: N (Asn) · Polar · K-D -3.5N214: G (Gly) · Special · K-D -0.4G215: Q (Gln) · Polar · K-D -3.5Q215216: P (Pro) · Special · K-D -1.6P217: E (Glu) · Acidic − · K-D -3.5E218: N (Asn) · Polar · K-D -3.5N219: N (Asn) · Polar · K-D -3.5N220: Y (Tyr) · Aromatic · K-D -1.3Y220221: K (Lys) · Basic + · K-D -3.9K222: T (Thr) · Polar · K-D -0.7T223: T (Thr) · Polar · K-D -0.7T224: P (Pro) · Special · K-D -1.6P225: P (Pro) · Special · K-D -1.6P225226: V (Val) · Hydrophobic · K-D 4.2V227: L (Leu) · Hydrophobic · K-D 3.8L228: D (Asp) · Acidic − · K-D -3.5D229: S (Ser) · Polar · K-D -0.8S230: D (Asp) · Acidic − · K-D -3.5D230231: G (Gly) · Special · K-D -0.4G232: S (Ser) · Polar · K-D -0.8S233: F (Phe) · Aromatic · K-D 2.8F234: F (Phe) · Aromatic · K-D 2.8F235: L (Leu) · Hydrophobic · K-D 3.8L235236: Y (Tyr) · Aromatic · K-D -1.3Y237: S (Ser) · Polar · K-D -0.8S238: R (Arg) · Basic + · K-D -4.5R239: L (Leu) · Hydrophobic · K-D 3.8L240: T (Thr) · Polar · K-D -0.7T240241: V (Val) · Hydrophobic · K-D 4.2V242: D (Asp) · Acidic − · K-D -3.5D243: K (Lys) · Basic + · K-D -3.9K244: S (Ser) · Polar · K-D -0.8S245: R (Arg) · Basic + · K-D -4.5R245246: W (Trp) · Aromatic · K-D -0.9W247: Q (Gln) · Polar · K-D -3.5Q248: E (Glu) · Acidic − · K-D -3.5E249: G (Gly) · Special · K-D -0.4G250: N (Asn) · Polar · K-D -3.5N250251: V (Val) · Hydrophobic · K-D 4.2V252: F (Phe) · Aromatic · K-D 2.8F253: S (Ser) · Polar · K-D -0.8S254: C (Cys) · Special · K-D 2.5C255: S (Ser) · Polar · K-D -0.8S255256: V (Val) · Hydrophobic · K-D 4.2V257: M (Met) · Hydrophobic · K-D 1.9M258: H (His) · Basic + · K-D -3.2H259: E (Glu) · Acidic − · K-D -3.5E260: A (Ala) · Hydrophobic · K-D 1.8A260261: L (Leu) · Hydrophobic · K-D 3.8L262: H (His) · Basic + · K-D -3.2H263: N (Asn) · Polar · K-D -3.5N264: H (His) · Basic + · K-D -3.2H265: Y (Tyr) · Aromatic · K-D -1.3Y265266: T (Thr) · Polar · K-D -0.7T267: Q (Gln) · Polar · K-D -3.5Q268: K (Lys) · Basic + · K-D -3.9K269: S (Ser) · Polar · K-D -0.8S270: L (Leu) · Hydrophobic · K-D 3.8L270271: S (Ser) · Polar · K-D -0.8S272: L (Leu) · Hydrophobic · K-D 3.8L273: S (Ser) · Polar · K-D -0.8S274: L (Leu) · Hydrophobic · K-D 3.8L275: G (Gly) · Special · K-D -0.4G275
Hydrophobic moment0.07
Mean K-D hydropathy-0.53
Approx. net charge-7
Projection angle100° / residue
The pale sector marks the direction of the hydrophobic face inferred from μH. This is a projection assumption, not a measured fold.
HydrophobicAromaticPolarBasic +Acidic −Specialhydrophobic faceμH arrow → hydrophobic face

The projection assumes an α-helix conformation; a long μH arrow indicates an amphipathic helix, common in antimicrobial peptides.Sequence > 30 aa — only termini and every fifth position are numbered because later turns share earlier wheel angles.

Method notes

Charge model: side-chain pKa D 3.9, E 4.1, C 8.5, Y 10.1, H 6.5, K 10.8, R 12.5 with EMBOSS termini. pI is estimated by binary search on modeled net charge. Hydropathy uses Kyte-Doolittle values; hydrophobic moment follows the Eisenberg alpha-helix vector-sum convention. When the basis is a parent-residue sequence, modified chemistry is intentionally not inferred.

Computed developability descriptors

Deterministic descriptors computed from the reviewed sequence or chemical structure (RDKit), each anchored to a literature method. These are computed estimates for developability interpretation — not experimental measurements — and are validated against independent reference implementations.

Sequence-derived

Computed from the standard parent-residue sequence; protein-origin metrics defined at any length.

Aliphatic index
62.98
Instability index
49.7

Above 40 — predicted unstable in vitro.

Boman index
1.54 kcal/mol
Molar extinction coefficient (280 nm)
42,400 M⁻¹·cm⁻¹

A280 (1 g/L) ≈ 1.42 · 42,775 M⁻¹·cm⁻¹ with 3 disulfides

Structure-derived descriptors are not shown because this identity has no resolved chemical structure (SMILES). This is a known coverage gap for disulfide-rich and unresolved peptidoforms, not a computation error.

03

Exposure / Absorption

7 records

What evidence describes systemic exposure or absorption?

Evidence records
7
Complete canonical measurements and observations attached to this domain.
Endpoint scope
4
Formal ADMET endpoints represented for this peptide.
Matched-context analysis
1
Quantitative results that may be analysed only with scientifically compatible records.
Reported-result review
6
Qualitative, narrative, or review-first results interpreted in their source context.
Endpoints in scopeCmaxTmaxBioavailabilityAUC
Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis
Quantitative results whose endpoint and context must still be matched before analysis.
1
Interpret as reported
Qualitative, narrative, or review-first findings preserved in source context.
6
Supporting context only
Reference, label, clinical, or supporting context for interpretation.
0
Review before analysis
Records whose present structure does not establish a safe analysis role.
0
Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

·
Bioavailability3 records · 0 matched-context · 3 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1
Observation

Absolute subcutaneous bioavailability for 3 mg and 4.5 mg doses were estimated to be similar to 1.5 mg although this has not been specifically studied.

Interpret as reported

human

Result: Qualitative or narrative result · Molecular form: not reported · Route: subcutaneous · Dulaglutide· 12.3 Pharmacokinetics · bioavailability higher dose estimated similar text ·... · Source: Primary reference linked

Reference
2

65 %

Use only explicitly reported fields

human

Result: Reported point value · Molecular form: not reported · Route: subcutaneous · Dulaglutide· 12.3 Pharmacokinetics · dulaglutide bioavailability 0.75mg · Absorption – Th... · Source: Primary reference linked

Reference
3

47 %

Use only explicitly reported fields

human

Result: Reported point value · Molecular form: not reported · Route: subcutaneous · Dulaglutide· 12.3 Pharmacokinetics · dulaglutide bioavailability 1.5mg · Absorption – The... · Source: Primary reference linked

Reference
AUC1 record · 0 matched-context · 1 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1
Observation

Site of subcutaneous administration (abdomen, upper arm, and thigh) had no statistically significant effect on the exposure to dulaglutide.

Interpret as reported

human

Result: Qualitative or narrative result · Molecular form: not reported · Route: subcutaneous · Dulaglutide· 12.3 Pharmacokinetics · exposure injection site no significant effect text ·... · Source: Primary reference linked

Reference
Cmax1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1

~ 114 ng/mL

Eligible when experimental context matches

TGA Product Information pharmacokinetics manual extraction · human · plasma

Result: Approximate quantitative measurement · Molecular form: not reported · Route: subcutaneous · Dose/window: multiple subcutaneous 1.5 mg doses in patients with type 2 diabetes · Time: steady state · Source: Primary reference linked

Reference
Tmax2 records · 0 matched-context · 2 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1

24-72 hours

86400-259200 seconds
Use only explicitly reported fields

human · plasma

Result: Interval measurement · Molecular form: not reported · Route: subcutaneous · Dulaglutide· 12.3 Pharmacokinetics · tmax range time to maximum · Following subcutaneous... · Source: Primary reference linked

Reference
2

48 hours

172800 seconds
Use only explicitly reported fields

human · plasma

Result: Reported point value · Molecular form: not reported · Route: subcutaneous · Dulaglutide· 12.3 Pharmacokinetics · tmax time to maximum median · Following subcutaneous... · Source: Primary reference linked

Reference
04

Distribution / Barrier

5 records

What is known about distribution, binding, permeability, or barrier crossing?

Evidence records
5
Complete canonical measurements and observations attached to this domain.
Endpoint scope
2
Formal ADMET endpoints represented for this peptide.
Matched-context analysis
2
Quantitative results that may be analysed only with scientifically compatible records.
Reported-result review
3
Qualitative, narrative, or review-first results interpreted in their source context.
Endpoints in scopeVdPlasma protein binding
Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis
Quantitative results whose endpoint and context must still be matched before analysis.
2
Interpret as reported
Qualitative, narrative, or review-first findings preserved in source context.
3
Supporting context only
Reference, label, clinical, or supporting context for interpretation.
0
Review before analysis
Records whose present structure does not establish a safe analysis role.
0
Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

·
Vd4 records · 2 matched-context · 2 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1

19.2 L

Eligible when experimental context matches

THPdb curated therapeutic product PK entry

Result: Reported point value · Molecular form: not reported · Route: Subcutaneous · Th1176 · Dulaglutide · single value · Subcutaneous · Hypoglycemic Agents · 6 · 1729|1730|... · Source: Primary reference linked

Reference
2

19.2 L

Eligible when experimental context matches

THPdb curated therapeutic product PK entry

Result: Reported point value · Molecular form: not reported · Th1176 · Dulaglutide · single value · NA · Hypoglycemic Agents · 1 · 1728 · NA · NA · Source: Primary reference linked

Reference
3

3.09 L

Use only explicitly reported fields

human

Result: Reported point value · Molecular form: not reported · Dulaglutide· 12.3 Pharmacokinetics · dulaglutide central volume of distribution · Distrib... · Source: Primary reference linked

Reference
4

5.98 L

Use only explicitly reported fields

human

Result: Reported point value · Molecular form: not reported · Dulaglutide· 12.3 Pharmacokinetics · dulaglutide peripheral volume of distribution · Dist... · Source: Primary reference linked

Reference
Plasma protein binding1 record · 0 matched-context · 1 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1
Observation

human plasma protein binding statement: dulaglutide shown not to bind to human plasma proteins; no numeric percent reported

Interpret as reported

Manual extraction from open-access GLP-1RA potency/PK article; human plasma protein-binding statement · human · plasma

Result: Qualitative or narrative result · Molecular form: not reported · Source: Primary reference linked

Reference
Barrier and permeability assay context

PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.

PAMPA
0

artificial membrane

Caco-2
0

cell monolayer

MDCK
0

cell monolayer

RRCK
0

cell monolayer

BBB
0

barrier evidence

05

Excretion / Persistence

3 records

What evidence describes clearance or persistence?

Evidence records
3
Complete canonical measurements and observations attached to this domain.
Endpoint scope
1
Formal ADMET endpoints represented for this peptide.
Matched-context analysis
2
Quantitative results that may be analysed only with scientifically compatible records.
Reported-result review
1
Qualitative, narrative, or review-first results interpreted in their source context.
Endpoints in scopeClearance
Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis
Quantitative results whose endpoint and context must still be matched before analysis.
2
Interpret as reported
Qualitative, narrative, or review-first findings preserved in source context.
1
Supporting context only
Reference, label, clinical, or supporting context for interpretation.
0
Review before analysis
Records whose present structure does not establish a safe analysis role.
0
Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

·
Clearance3 records · 2 matched-context · 1 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1

0.111 L/h

Eligible when experimental context matches

THPdb curated therapeutic product PK entry

Result: Reported point value · Molecular form: not reported · Route: Subcutaneous · Th1176 · Dulaglutide · single value · Subcutaneous · Hypoglycemic Agents · 6 · 1729|1730|... · Source: Primary reference linked

Reference
2

0.111 L/h

Eligible when experimental context matches

THPdb curated therapeutic product PK entry

Result: Reported point value · Molecular form: not reported · Th1176 · Dulaglutide · single value · NA · Hypoglycemic Agents · 1 · 1728 · NA · NA · Source: Primary reference linked

Reference
3

0.142 L/h

Use only explicitly reported fields

human

Result: Reported point value · Molecular form: not reported · Dulaglutide· 12.3 Pharmacokinetics · clearance single · Elimination The apparent populati... · Source: Primary reference linked

Reference
06

Evidence landscape

15 records

Cross-domain evidence distribution and measurement-level detail; the domain modules above show evidence in context, and every row remains available for audit here.

Evidence landscape

A cross-domain view of evidence volume, scientifically permitted analysis use, and source traceability.

ADMET domain
Eligible when context matches
Interpret as reported
Supporting context only
Review before analysis
Exposure / Absorption
7 evidence records
1
6
0
0
Distribution / Barrier
5 evidence records
2
3
0
0
Metabolic & Proteolytic Stability
0 evidence records
0
0
0
0
Excretion / Persistence
3 evidence records
2
1
0
0
Toxicity / Safety
0 evidence records
0
0
0
0
Endpoint distribution

Top evidence-bearing endpoint questions.

Volume Of Distribution
4
Bioavailability
3
Clearance
3
Time To Max Concentration
2
Area Under Curve
1
Max Concentration
1
Plasma Protein Binding
1
Assay context

Broad context buckets, useful before comparing values.

In vivo / route
15
Traceability

Reference-link availability for measurement-level audit.

Linked reference
15
Not linked
0
All evidence index

Every evidence record remains available for audit and drilldown. Counts describe evidence volume, not confidence.

#ADMET domainEndpointReported valueResult typeAnalysis useAssay / modelConditionReference
1
Exposure / Absorption
Exposure
Max Concentration
~ 114 ng/mL
Approximate quantitative measurementEligible when experimental context matchesTGA Product Information pharmacokinetics manual extraction · human · plasmaRoute: subcutaneous · Time: steady state · Dose/window: multiple subcutaneous 1.5 mg doses in patients with type 2 diabetes · Source reports mean peak exposure at steady state · steady stat...
Reference
Primary reference linked
2
Excretion / Persistence
Persistence
Clearance
0.111 L/h
Reported point valueEligible when experimental context matchesTHPdb curated therapeutic product PK entrythpdb_clearance_v0_1 · Drugs Used in Diabetes
Reference
Primary reference linked
3
Excretion / Persistence
Persistence
Clearance
0.111 L/h
Reported point valueEligible when experimental context matchesTHPdb curated therapeutic product PK entryRoute: Subcutaneous · thpdb_clearance_v0_1 · Drugs Used in Diabetes
Reference
Primary reference linked
4
Distribution / Barrier
Distribution
Volume Of Distribution
19.2 L
Reported point valueEligible when experimental context matchesTHPdb curated therapeutic product PK entrythpdb_volume_distribution_v0_1 · Drugs Used in Diabetes
Reference
Primary reference linked
5
Distribution / Barrier
Distribution
Volume Of Distribution
19.2 L
Reported point valueEligible when experimental context matchesTHPdb curated therapeutic product PK entryRoute: Subcutaneous · thpdb_volume_distribution_v0_1 · Drugs Used in Diabetes
Reference
Primary reference linked
6
Distribution / Barrier
Distribution
Plasma Protein Binding
Observation

human plasma protein binding statement: dulaglutide shown not to bind to human plasma proteins; no numeric percent reported

Qualitative or narrative resultInterpret as reportedManual extraction from open-access GLP-1RA potency/PK article; human plasma protein-binding statement · human · plasmaThe article states non-lipidated GLP-1 receptor agonists Dulaglutide and Exenatide have been shown not to bind to human plasma proteins. Store as text evidence only · do not convert the qua...
Reference
Primary reference linked
7
Exposure / Absorption
Exposure
Time To Max Concentration
24-72 hours
86,400-259,200 seconds
Interval measurementUse only explicitly reported fieldshuman · plasmaRoute: subcutaneous
Reference
Primary reference linked
8
Exposure / Absorption
Exposure
Time To Max Concentration
48 hours
172,800 seconds
Reported point valueUse only explicitly reported fieldshuman · plasmaRoute: subcutaneous
Reference
Primary reference linked
9
Exposure / Absorption
Exposure
Bioavailability
65 %
Reported point valueUse only explicitly reported fieldshumanRoute: subcutaneous
Reference
Primary reference linked
10
Exposure / Absorption
Exposure
Bioavailability
47 %
Reported point valueUse only explicitly reported fieldshumanRoute: subcutaneous
Reference
Primary reference linked
1–10 / 15
07

Product context

Product-level route, label, and clinical context that frames peptide-level evidence. A peptide-level summary only; product pages keep the full drilldown.

No product association in this release

This peptide is currently interpreted from sequence, structure, physicochemical, and ADMET evidence only.

Browse products
08

Identity & reference map

15 sources

Reference-level support for checking reported names, sequence notation, and peptide identity agreement.

·
Summary4 reference groups
Identity type
canonical sequence
Reported notation
0
Reference groups
4
Measurements
15
ATL peptide ID
ATLPC0015133
Identity concordance
Identity concordance
Exact reported notation

Reported sequence string matches the current peptide notation.

0 / 15
Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 15
Different notation

Reported notation does not resolve to the current display sequence.

0 / 15
Source sequence not captured

No source-specific sequence was captured for comparison; this is not interpreted as agreement or disagreement.

15 / 15
Reported sequence notation

No source-specific sequence notation has been captured in the current identity references.

Current identity
HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGGGGGGSGGGGSGGGGSAESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG
Reported names
No distinct human-readable aliases are exposed.
Reference map4 reference groups
Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

ReferenceSupportsReported identityRecords
Reference
Open
DistributionExposurePersistence
Area Under Curve, Bioavailability, Clearance, Time To Max Concentration +1 more
No reported alias
9 identity
9 evidence
Reference
Open
DistributionPersistence
Clearance, Volume Of Distribution
No reported alias
4 identity
4 evidence
Reference
Open
Exposure
Max Concentration
No reported alias
1 identity
1 evidence
Reference
Open
Distribution
Plasma Protein Binding
No reported alias
1 identity
1 evidence
09

Data access & reproducibility

Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.

·
Record scopePublic release
ATL peptide ID
ATLPC0015133
Identity type
canonical sequence
ADMET endpoints
7
Evidence records
15
Reference groups
4
Release view
Public release
Data access

Structured peptide profile

JSON

Peptide-specific profile used by this page, including identity and evidence context.

Open JSON

Peptide catalogue

TSV

Complete frozen peptide table. Filter the ATL peptide ID column locally to isolate this record.

Download catalogue

Measurement catalogue

TSV

Complete frozen measurement table. Join or filter by ATL peptide ID for peptide-level analysis.

Download measurements
Programmatic access

The request returns the same structured peptide record used by this profile. The tabular downloads are complete frozen release tables and should be filtered locally by ATL peptide ID.

Open endpoint
GET /api/v1/peptides/ATLPC0015133
open
curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0015133' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'
ADMETatlas
peptide evidence atlas

ADMETatlas is an open, curated atlas of ADMET evidence for therapeutic peptides — spanning developability, membrane permeability and blood–brain-barrier transport, immune-recognition context, and approved-product context. Every measurement stays linked to its original source, with stable identifiers and transparent curation, so results can be traced, cited, and reproduced.

Browse
PeptidesProductsEvidenceContext signalsDescriptors
Resource
DevelopabilityComparatorManualExplanationsStatisticsDownloadAbout
Stack
  • RDKit
  • Mol*
  • Python
  • FastAPI
  • PostgreSQL
  • Next.js
  • React
  • TypeScript
  • Tailwind CSS
  • Apache ECharts
© 2026 ADMETatlas, an academic peptide ADMET evidence atlas.